NorthWest Biotherapeutics Inc (NWBO)

[Adam_Feuerstein]

Not necessarily, if the DCVax manufacturing or quality issue came up later in the study.

Remember, DCVax is custom made for each patient enrolled in the study. There is going to be inherent variability in this process. Each DCVax product must meet certain potency standards before being released for injection into the patient.

The screening halt could have been triggered by a series of bad DCVax batches or something going wrong in the manufacturing process. If NWBO loses the ability to make DCVax, the study would have to halt enrollment but not necessarily halt treatment for patients enrolled previously,